Molecular diagnosis of breast carcinoma

The approach to breast cancer is in continuous progress, not only due to the incorporation of new drugs and therapeutic strategies, but also due to advances in the staging and diagnostic processes. In recent years we have seen how the genomic study made it possible to classify breast cancer into different subgroups (Luminales, HER2, Triple negative) and how the biology of the tumor was incorporated for the first time in the staging of the American Joint Committee on Cancer (AJCC , 8th ed).

In this course we propose to update the diagnosis of breast cancer, addressing from the traditional methods that persist in our days, to the new technologies already recognized and implemented in the daily routine, as well as other more avant-garde ones that are making their way little by little.

General objective of the course:

Update the diagnosis of breast cancer, addressing from the traditional methods that persist today, to the new technologies already recognized and implemented in the daily routine, as well as other more avant-garde ones that are gradually making their way. 

Specific objectives:

• Know the classic markers of prognosis and treatment, as well as biomarkers for targeted therapies (HER2, PD-L1) and the role of intratumoral lymphocytes (TILs).
• To know the genomic risk platforms currently used for the decision of chemotherapy treatment in patients with estrogen positive and HER2 negative tumors.
• Understand the role of digitization and artificial intelligence in the diagnosis of breast cancer.
• Learn the potential of liquid biopsy, proteomics and mass sequencing.

Target audience:

Oncologists, pathologists, breast unit clinicians, biologists, biomedicians, residents and pathology students.

Enrollment periods:

• 1r Period: from 11/1/2021 to 28/3/2021
• 2n Period: from 1/4/2021 to 27/6/2021
• 3r Period: from 1/7/2021 to 26/9/2021
• 4t Period: from 1/10/2021 to 26/12/2021

Sponsors: